Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling

Cancer Research

Volumn 74, Issue 3, 2014, Pages 921-931

  Pishas, Kathleen I ^a,b   Neuhaus, Susan J ^b,e   Clayer, Mark T ^d   Schreiber, Andreas W ^c,f   Lawrence, David M ^c,f   Perugini, Michelle ^d,g   Whitfield, Robert J ^e   Farshid, Gelareh ^b,h   Manavis, Jim ^a   Chryssidis, Steve ⁱ   Mayo, Bronwen J ^b   Haycox, Rebecca C ^b   Ho, Kristen ^b   Brown, Michael P ^c,e,g   D'Andrea, Richard J ^c,g,j   Evdokiou, Andreas ^b,k   Thomas, David M ^l   Desai, Jayesh ^m   Callen, David F ^b   Neilsen, Paul M ^a,b  

^a HANSON INSTITUTE   (Australia)

^b Rehabilitation Research Centre   (Australia)

^c Chemokine Biology Laboratory Centre for Molecular Pathology School of Molecular and Biomedical Science   (Australia)

^d Department of Orthopaedics and Trauma ^*  (Australia)

^e ROYAL ADELAIDE HOSPITAL   (Australia)

^f ACRF Cancer Genomics Facility SA Pathology   (Australia)

^g CENTRE FOR CANCER BIOLOGY   (Australia)

^h PathCentre   (Australia)

ⁱ QUEEN ELIZABETH HOSPITAL   (Australia)

^j Basil Hetzel Institute and Queen Elizabeth Hospital   (Australia)

^k UNIVERSITY OF ADELAIDE   (Australia)

^l PETER MACCALLUM CANCER CENTRE   (Australia)

^m ROYAL MELBOURNE HOSPITAL   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CLUSTER ANALYSIS; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; EPIGENOMICS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PIPERAZINES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MDM2; SARCOMA; SIGNAL TRANSDUCTION; TRANSCRIPTOME; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84893837391     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2424     Document Type: Article

References (44)

1. Chao J, Chow WA, Somlo G. Novel targeted therapies in the treatment of soft-tissue sarcomas. Expert Rev Anticancer Ther 2010;10: 1303-11.
2. Neilsen PM, Pishas KI, Callen DF, Thomas DM. Targeting the p53 pathway in Ewing sarcoma. Sarcoma 2011;2011:746939.
3. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-9.
4. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006;6:909-23.
5. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-8.
6. Coindre JM, Pedeutour F, Aurias A. Well-differentiated and dedifferentiated liposarcomas. Virchows Arch 2010;456:167-79.
7. Muller CR, Paulsen EB, Noordhuis P, Pedeutour F, Saeter G, Myklebost O. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int J Cancer 2007;121:199-205.
8. Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A 2006;103: 1888-93.
9. Ray-Coquard I, Blay JY, Italiano A, Le Cesne A, Penel N, Zhi J, et al. Effect of theMDM2antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol 2012; 13:1133-40.
10. Cheok CF, Verma CS, Baselga J, Lane DP. Translating p53 into the clinic. Nat Rev Clin Oncol 2011;8:25-37.
11. Clinical Trials gov. U.S National Institute of Health. [Updated 2013 Jun 3; cited 2013 Jun 6]. Available from: http://www.clinicaltrials.gov.
12. Ding Q, Zhang Z, Liu JJ, Jiang N, Zhang J, Ross TM, et al. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J Med Chem. 2013 Jul [Epub ahead of print]
13. Pishas KI, Neuhaus SJ, Clayer MT, Adwal A, Brown MP, Evdokiou A, et al. Pre-activation of the p53 pathway through Nutlin-3a sensitises sarcomas to drozitumab therapy. Oncol Rep 2013;30: 471-7.
14. Singh B, Li R, Xu L, Poluri A, Patel S, Shaha AR, et al. Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck 2002;24:437-42.
15. Wang G, Firoz EF, Rose A, Blochin E, Christos P, Pollens D, et al. MDM2expression and regulation in prostate cancer racial disparity. Int J Clin Exp Pathol 2009;2:353-60.
16. NeilsenPM, Cheney KM, Li CW, Chen JD, Cawrse JE, Schulz RB, et al. Identification of ANKRD11 as a p53 coactivator. J Cell Sci 2008;121: 3541-52.
17. Pishas KI, Al-Ejeh F, Zinonos I, Kumar R, Evdokiou A, Brown MP, et al. Nutlin-3a is a potential therapeutic for Ewing sarcoma. Clin Cancer Res 2011;17:494-504.
18. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol 2013;14:R36.
19. HTSeq. Analysing high-throughput sequencing data with Python. [cited 2013 Jun 12]. Available from: http://www-huber.embl.de/ users/anders/HTSeq.
20. Perugini M, Iarossi DG, Kok CH, Cummings N, Diakiw SM, Brown AL, et al. GADD45A methylation predicts poor overall survival in acute myeloid leukemia and is associated with IDH1/2 and DNMT3A mutations. Leukemia 2013;27:1588-92.
21. Perugini M, Kok CH, Brown AL, Wilkinson CR, Salerno DG, Young SM, et al. Repression of Gadd45alpha by activated FLT3 and GM-CSF receptor mutants contributes to growth, survival and blocked differentiation. Leukemia 2009;23:729-38.
22. Zhang F, Tagen M, Throm S, Mallari J, Miller L, Guy RK, et al. Wholebody physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration. Drug Metab Dispos 2011;39:15-21.
23. Gu L, Zhu N, Findley HW, Zhou M. MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2. Leukemia 2008;22:730-9.
24. Carol H, Reynolds CP, Kang MH, Keir ST, Maris JM, Gorlick R, et al. Initial testing of theMDM2 inhibitor RG7112 by the pediatric preclinical testing program. Pediatr Blood Cancer 2013;60:633-41.
25. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012;483:570-5.
26. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008;9:402-12.
27. Ramachandran K, Gopisetty G, Gordian E, Navarro L, Hader C, Reis IM, et al. Methylation-mediated repression of GADD45alpha in prostate cancer and its role as a potential therapeutic target. Cancer Res 2009;69:1527-35.
28. Wang W, Huper G, Guo Y, Murphy SK, Olson JA Jr, Marks JR. Analysis of methylation-sensitive transcriptome identifies GADD45a as a frequently methylated gene in breast cancer. Oncogene 2005;24: 2705-14.
29. Guo W, Dong Z, Guo Y, Chen Z, Kuang G, Yang Z. Methylationmediated repression ofGADD45AandGADD45Gexpression in gastric cardia adenocarcinoma. Int J Cancer 2013;133:2043-53.
30. Al-Romaih K, Sadikovic B, Yoshimoto M, Wang Y, Zielenska M, Squire JA. Decitabine-induced demethylation of 50 CpG island in GADD45A leads to apoptosis in osteosarcoma cells. Neoplasia 2008;10:471-80.
31. Tong T, Ji J, Jin S, Li X, Fan W, Song Y, et al. Gadd45a expression induces Bim dissociation from the cytoskeleton and translocation to mitochondria. Mol Cell Biol 2005;25:4488-500.
32. Vairapandi M, Azam N, Balliet AG, Hoffman B, Liebermann DA. Characterization of MyD118, Gadd45, and proliferating cell nuclear antigen (PCNA) interacting domains. PCNA impedes MyD118 AND Gadd45-mediated negative growth control. J Biol Chem 2000;275:16810-9.
33. Zhang W, Hoffman B, Liebermann DA. Ectopic expression of MyD118/ Gadd45/CR6 (Gadd45beta/alpha/gamma) sensitizes neoplastic cells to genotoxic stress-induced apoptosis. Int J Oncol 2001;18:749-57.
34. Sonnemann J, Palani CD, Wittig S, Becker S, Eichhorn F, Voigt A, et al. Anticancer effects of the p53 activator nutlin-3 in Ewing's sarcoma cells. Eur J Cancer 2011;47:1432-41.
35. Miyachi M, Kakazu N, Yagyu S, Katsumi Y, Tsubai-Shimizu S, Kikuchi K, et al. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells. Clin Cancer Res 2009;15:4077-84.
36. D'Arcy P, Ryan BA, Brodin B. Reactivation of p53 function in synovial sarcoma cells by inhibition of p53-HDM2 interaction. Cancer Lett 2009;275:285-92.
37. Nakano Y, Naoe T, Kiyoi H, Kitamura K, Minami S, Miyawaki S, et al. Prognostic value of p53 gene mutations and the product expression in de novo acute myeloid leukemia. Eur J Haematol 2000;65:23-31.
38. Trecca D, Longo L, Biondi A, Cro L, Calori R, Grignani F, et al. Analysis of p53 gene mutations in acute myeloid leukemia. Am J Hematol 1994;46:304-9.
39. Takekawa M, Saito H. A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK. Cell 1998;95:521-30.
40. Harkin DP, Bean JM, Miklos D, Song YH, Truong VB, Englert C, et al. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell. 1999;97:575-86.
41. Gao M, Li X, Dong W, Jin R, Ma H, Yang P, et al. Ribosomal protein S7 regulates arsenite-induced GADD45alpha expression by attenuating MDM2-mediated GADD45alpha ubiquitination and degradation. Nucleic Acids Res 2013;41:5210-22.
42. Li J, Tan J, Zhuang L, Banerjee B, Yang X, Chau JF, et al. Ribosomal protein S27-like, a p53-inducible modulator of cell fate in response to genotoxic stress. Cancer Res 2007;67:11317-26.
43. Xiong X, Zhao Y, He H, Sun Y. Ribosomal protein S27-like and S27 interplay with p53-MDM2 axis as a target, a substrate and a regulator. Oncogene 2011;30:1798-811.
44. Zhu Y, Poyurovsky MV, Li Y, Biderman L, Stahl J, Jacq X, et al. Ribosomal protein S7 is both a regulator and a substrate of MDM2. Mol Cell 2009;35:316-26.